ADMS News and Press, Adamas Pharmaceuticals Inc. From 06/17/20

Gainers:  ELOX +52.1% . ORN +17.7% . TMBR +8.5% . ABM +8.0% . DADA +7.2% . More news on: Eloxx Pharmaceuticals, Inc., Orion Group Holdings, Inc., Timber Pharmaceuticals, Inc., Stocks on the move, , Read more ...

Citing "limited" commercial opportunity and the need to conduct another late-stage clinical trial, Adamas Pharmaceuticals (NASDAQ: ADMS ) has decided to terminate development of ADS-5102 (amantadine) extended-release capsules for the treatment multiple sclerosis (MS) patients with walkin...

EMERYVILLE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the completion of its evaluation of AD...

Heron Reports Positive Results From Mid-Stage Knee Replacement Trial Heron Therapeutics (HRTX) announced that its Phase 2b clinical trial Study 209 has provided positive data with regard to HTX-011. The trial involved testing the drug candidate on patients undergoing total knee arthropla...

The FDA accepts for review Adamas Pharmaceuticals' (NASDAQ: ADMS ) supplemental marketing application seeking approval to use Gocovri (amantadine) to treat OFF episodes in Parkinson's disease (PD) patients receiving levodopa-based therapy. The agency's action date is February 1, 2021....

EMERYVILLE, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that its supplemental New Drug Applica...

EMERYVILLE, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the...

EMERYVILLE, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been issued a new patent (no. 10...

Adamas Pharmaceuticals, Inc. (ADMS) Q1 2020 Earnings Conference Call May 07, 2020 05:00 PM ET Company Participants Peter Vozzo - Investor Relations Neil McFarlane - Chief Executive Officer Vijay Shreedhar - Chief Commercial Officer Chris Prentiss - Chief Financial Officer. C...

Adamas Pharma (NASDAQ: ADMS ): Q1 GAAP EPS of -$0.59 beats by $0.23 . More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...